摘要
目的探讨在肝移植术后应用胸腺肽α1对急性排斥反应发生的影响及对T细胞免疫功能的影响。方法20例原发性肝癌行肝移植患者,完全随机化(随机数字表法)分为2组,每组10例。对照组移植术后仅行常规免疫抑制剂方案;实验组于术后第1d开始皮下注射胸腺肽α1,1.6mg/次,2次/周,至少持续1个月,免疫抑制剂方案同对照组。术后行肝穿刺活检,比较2组间急性排斥反应发生率;于术前1d及术后1周、2周及1个月检查2组细胞免疫功能。结果2组间急性排斥反应发生率差异无统计学意义(P>0.05);术后2周及1个月实验组CD4+、CD8+T淋巴细胞数及CD4+/CD8+比值比对照组明显升高(P<0.05)。结论肝移植术后,在常规使用免疫抑制剂条件下,近期应用胸腺肽α1不增加急性排斥反应发生几率。胸腺肽α1可显著提高肝移植术后患者的细胞免疫功能。
Objective To observe the effects of Thymosin α1（Tα1） on acute rejection after liver transplantation and immune function of T cells. Methods Twenty recipients of liver transplantation due to primary hepatic carcinoma were divided into two groups： Tα1 group （n= 10） and control group （n= 10）. Tα1 group received subcutaneous injection of Tα1 1.6 mg on the first day after liver transplantation and then twice a week for at least one month. Both Tα1 group and control group took same immunodepressants. Core biopsies were carried to compare the incidence rate of acute rejection between Tα1 group and control group. Peripheral T cellular immune function in these two groups was detected on 1 d before, 1 week, 2 weeks and 1 month after transplantation. Results There was not significant difference of incidence rate of acute rejection between Tα1 group and control group （P〉0.05）. In the Tα1 group, CD4^＋ , CD8^＋ lymphocyte cell counts and the CD4^＋/CD8^＋ ratio were significantly higher than those in the control group in 2 weeks and 1 month after transplantation （P〈0.05）. Conclusion Use of Tα1 in recipients who also takes rountine immunosuppressants dose not increase the risk of occurring acute rejection after liver transplantation. Tα1 can significantly increase CD4^＋ , CD8^＋ counts and CD4^＋/CD8^＋ ratio, which shows that Tα1 may improve recipients＇ cellular immune function.
出处
《中国普外基础与临床杂志》
CAS
2008年第6期430-434,共5页
Chinese Journal of Bases and Clinics In General Surgery
